Oragenics Announces Test Marketing of Probiora3(TM) Chewable Tablets
09 Maggio 2008 - 4:11PM
Marketwired
ALACHUA, FL announced today the test marketing of its oral
probiotic product, Probiora3. The chewable tablets help to whiten
teeth and improve breath though the use of a unique combination of
safe, naturally occurring bacteria that are released in the mouth
by chewing on a mint-flavored tablet that the Company has designed
to be used twice daily.
The Company believes that further analysis and possible further
testing of the product will show that Probiora3 will also improve
oral health for those millions of people who suffer from chronic
tooth and gum problems, although no such representations can be
made at this time. Probiora3 is the first of the Company's many
products to be brought to market.
The Company expects to begin direct-to-consumer sales within the
next month through a subsidiary company and to bring the product to
the public's attention through the media.
Rick Welch, Chairman of Oragenics' Board, stated, "I am
enthusiastic about the current and potential consumer benefits of
Probiora3, and recognize that it marks the first of what we hope
are a long line of pharma and non-pharma products to reach market
in time to come."
Dr. Jeffrey D. Hillman, Oragenics' Chief Scientific Officer,
added, "Probiora3 is a blend of three naturally occurring and
beneficial oral bacteria. The chewable tablet is the first of our
planned products for diagnosing and treating a number of infectious
diseases including those that affect the mouth."
About Oragenics
Oragenics, Inc. is a biopharmaceutical company with a pipeline
of proprietary technologies. The Company has a number of products
in discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases.
Our core pipeline includes products and supporting platform
technologies for use in the treatment and diagnosis of bacterial
infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect Oragenics' current views with respect to
future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-QSB, and
other factors detailed from time to time in filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.
Contact: Oragenics, Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Grafico Azioni Oragenics (AMEX:ONI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Oragenics (AMEX:ONI)
Storico
Da Set 2023 a Set 2024